CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Study to Evaluate the Efficacy and Safety of SBRT as an Adjunctive Intervention for Oligoresidual Disease in EGFR Mutant NSCLC With First-Line Osimertinib Treatment

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05998993
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:37.437513+00:00
Published At: 2023-08-21T00:00:00+00:00
Record Updated At: 2023-08-21
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["EGF-R Positive Non-Small Cell Lung Cancer", "Non Small Cell Lung Cancer", "EGFR Exon 19 Deletion", "EGFR Exon 21 Mutation", "EGFR G719X"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-08-21"
protocolSection.identificationModule.nctId: "NCT05998993"
protocolSection.identificationModule.officialTitle: "Phase II Study to Evaluate the Efficacy and Safety of SBRT as an Adjunctive Intervention for Oligoresidual Disease in EGFR Mutant NSCLC With First-Line Osimertinib Treatment"
protocolSection.statusModule.overallStatus: "NOT_YET_RECRUITING"
protocolSection.designModule.phases: ["NA"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.